Drug Topics

JUNE 6, 2025

2026 Edition. Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our free Drug Topics newsletter. REFERENCES 1. Yellow Book. Updated April 23, 2025. Accessed May 16, 2025. The Immunization Action Coalition. Travel Vaccines. Updated October 11, 2024.

Vaccines 341

Vaccines Immunization Compounding Specialty Pharmacies 341

Drug Topics

JUNE 17, 2025

1 The company said it plans to initiate phase 3 studies in 2026 to further evaluate the therapy. Positive results have been announced from a phase 2a clinical trial evaluating the safety, pharmacokinetics and efficacy of PP405 for the treatment of androgenetic alopecia in adult patients, Pelage Pharmaceuticals announced in a release.

Specialty Pharmacies 190

Specialty Pharmacies Compounding Independent Pharmacies Immunization 190

The FDA Law Blog

FEBRUARY 2, 2025

This also includes additional requirements for pharmacies that engage in sterile and complex nonsterile compounding. California pharmacists are still able to provide the oral therapeutics without requiring you to visit your primary care physician through January 1, 2026.

Packaging 59

Packaging Documentation Compounding 59

pharmaphorum

JUNE 27, 2022

Tazverik is a first-in-class EZH2a inhibitor that was cleared by the FDA in 2020 as a third-line or later treatment for adults with relapsed or refractory follicular lymphoma (FL) whose tumours have an EZH2 mutation. Ipsen’s CVR offer includes $0.30 The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.

Compounding 110

Compounding FDA 110

pharmaphorum

APRIL 24, 2022

In a statement, the drugmaker said “we stand by the safety of aducanumab, and we look forward to upcoming data readouts to continue to provide important information on the science of this new class of compound.” Biogen has now drawn up its plans for the confirmatory study that could be the key to getting Aduhelm back on track.

Compounding 52

Compounding FDA 52

PharmaShots

FEBRUARY 22, 2023

Some of its FDA-approved competitors include: Patents7 Eli Lilly carries big expectations from Trulicity to boost its revenue. In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). Trulicity has been a part of over 2.8

Insurance 64

Insurance Compounding Dosage Communication 64

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. However, Invokana is likely to continue to lose market share (forecast 9MM CAGR decline of 14.6%), due to an FDA boxed warning regarding diabetic ketoacidosis and increased risk of lower limb amputations.

Labelling 52

Labelling Pharmaceutical Companies Compounding Pharmaceutical Companies 52